Abdel-Aziz et al., reported a series of novel pyrazoline derivatives linked to a 4-methylsulfonylphenyl scaffold (compounds 18a–q) were synthesized and evaluated for their antitumor activity, enzyme inhibition, and cell cycle effects. These compounds were tested against 59 cancer cell lines, and several showed significant cytotoxic effects. Notably, compounds 18b, 18c, 18f, 18g, 18h, and 18n demonstrated potent antitumor activity, particularly against HL60, MCF-7, and MDA-MB-231 cell lines. Compounds 18g and 18h were the most effective, with IC50 values of 10.43 and 8.99 μM against HL60, 11.7 and 12.4 μM against MCF-7, and 4.07 and 7.18 μM against MDA-MB-231, respectively. Additionally, these compounds significantly inhibited VEGFR2 kinase, with IC50 values of 0.218, 0.168, and 0.135 μM for compounds 18c, 18g, and 18h, respectively, compared to the reference drug sorafenib (IC50 = 0.041 μM). Compounds 18g and 18h also showed substantial inhibition of HER2 kinase and moderate inhibition of EGFR kinase. Further, the most active compounds (18c, 18f, and 18h) were found to induce cell cycle arrest at the S/G2 phase in HL-60 cells, reduce Bcl-2 protein expression, and increase Bax, caspase-3, and caspase-9 expression levels, indicating apoptotic activity. Molecular docking studies provided insights into the interaction modes of these pyrazoline derivatives with EGFR, HER2, and VEGFR2 kinases, highlighting the structural features necessary for their antitumor activity. Overall, the study suggests that these novel pyrazoline derivatives are promising candidates for further development as anticancer agents due to their potent antitumor activities and ability to inhibit key receptor tyrosine kinases involved in cancer cell proliferation and survival.
Therefore Paper will be accepted in RSC Advances after below minor revision
1. Reaction Schemes and figures should be placed in the main text to get clear attention of the audience .
2. The conclusion should be more specific .

Author modified the given corrections correctly.
Therefore, I am accepting this publication in RSC advances.